FDA
-
-
-
-
-
-
-
Summit ivonescimab shows OS hazard ratio of 0.76 in lung cancer trial
-
-
-
-
-
-
-
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
-
-
-
-
-
-
-
Summit Therapeutics to present ivonescimab data at ELCC 2026
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
-
-
-
-
-
-
Summit Therapeutics files FDA application for cancer drug ivonescimab
-
-
-
-
-
-
-
Summit Therapeutics to Present at Upcoming Investor Conferences
-
-
-
-
-
-
-
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
-
327,987 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

